Cargando…
Combination of yttrium-90 radioembolization with stereotactic body radiation therapy in the treatment of portal vein tumor thrombosis
PURPOSE: Portal vein tumor thrombosis (PVTT) from cancer involving the liver carries a dismal prognosis, with median overall survival (OS) ranging from 2 to 5 months. While treatment with yttrium-90 ((90)Y) radioembolization alone may improve outcomes, overall prognosis remains poor. We hypothesize...
Autores principales: | Liu, Jason, Ladbury, Colton, Amini, Arya, Glaser, Scott, Kessler, Jonathan, Lee, Aram, Chen, Yi-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Radiation Oncology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497860/ https://www.ncbi.nlm.nih.gov/pubmed/34619828 http://dx.doi.org/10.3857/roj.2021.00213 |
Ejemplares similares
-
Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival
por: Somma, Francesco, et al.
Publicado: (2019) -
Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023) -
A Systematic Review on the Safety and Effectiveness of yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Jia, Zhongzhi, et al.
Publicado: (2016) -
Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated with Yttrium-90 Glass Microsphere Radioembolization: Preliminary Results
por: Pracht, M., et al.
Publicado: (2013) -
Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization
por: Xing, Minzhi, et al.
Publicado: (2018)